Health
Oncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep’s Potential Across Gastrointestinal Tumors
Translational data demonstrate induction of both innate and adaptive antiviral and anti-tumor specific immune responses capable of controlling tumor growthSAN DIEGO, May 22, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage company developing pelareorep, today announced translational data from the GOBLET and AWARE-1 trials will be presented at the 2026 American Society of Clinical Oncology (“ASCO”) Annual Meeting at McCormick Place
About this update from Oncolytics Biotech Inc.
[{"type":"image","alt":"Oncolytics Biotech, Inc.","displaySize":"","headline":null,"caption":"Oncolytics Biotech, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":95,"url":"https://media.zenfs.com/en/globenewswire.com/e1054990e7265558e662ea8dc1b99116"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/94wAQZ5b5jEQpnQKACjROw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzMw--/https://media.zenfs.com/en/globenewswire.com/e1054990e7265558e662ea8dc1b99116","width":300,"height":95},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/94wAQZ5b5jEQpnQKACjROw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzMw--/https://media.zenfs.com/en/globenewswire.com/e1054990e7265558e662ea8dc1b99116","width":300,"height":95}},"lazy":false},{"type":"text","content":"Translational data demonstrate induction of both innate and adaptive antiviral and anti-tumor specific immune responses capable of controlling tumor growth","length":155,"tagName":"p"},{"type":"text","content":"SAN DIEGO, May 22, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage company developing pelareorep, today announced translational data from the GOBLET and AWARE-1 trials will be presented at the 2026 American Society of Clinical Oncology (“ASCO”) Annual Meeting at McCormick Place, Chicago, Illinois, from May 29-June 2, 2026. Pelareorep is an investigational, systemically active immunotherapy that promotes potentially protective immune responses, including the upregulation of key inflammatory cytokines resulting in the formation of tertiary lymphoid structures and the expansion of tumor-infiltrating lymphocytes.","length":683,"tagName":"p"},{"type":"text","content":"“These findings demonstrate that pelareorep works by expanding preexisting tumor-reactive immune cells rather than introducing new antigens,” said Dr. Richard Vile, Ph.D., Professor of Immunology at the Mayo Clinic and Oncolytics Scientific Advisory Board Member. “This further underscores Oncolytics’ continued commitment to define the mechanisms by which pelareorep engages the immune system and illustrates the progress being made in developing a differentiated immunotherapy to improve treatment options for difficult-to-treat cancers.”","length":545,"tagName":"p"},{"type":"text","content":"“KRAS-mutant tumors remain among the most challenging to treat wi...